Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 21-30 of 108 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2013Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effectsVandyke, K.; Fitter, S.; Drew, J.; Fukumoto, S.; Schultz, C.; Sims, N.; Yeung, D.; Hughes, T.; Zannettino, A.
2014Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombinationParker, W.; Phillis, S.; Yeung, D.; Hughes, T.; Scott, H.; Branford, S.
2010Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemiaSaglio, G.; Kim, D.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R.; Hochhaus, A.; Hughes, T.; Gallagher, N.; Hoenekopp, A.; Haque, A.; Dong, M.; Larson, R.; Kantarjian, H.
2017CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressorsHughes, A.; Clarson, J.; Tang, C.; Vidovic, L.; White, D.; Hughes, T.; Yong, A.
2011Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialKantarjian, H.; Hochhaus, A.; Saglio, G.; de Souza, C.; Flinn, I.; Stenke, L.; Goh, Y.; Rosti, G.; Nakamae, H.; Gallagher, N.; Hoenekopp, A.; Blakesley, R.; Larson, R.; Hughes, T.
2012Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upLarson, R.; Hochhaus, A.; Hughes, T.; Clark, R.; Etienne, G.; Kim, D.; Flinn, I.; Kurokawa, M.; Moiraghi, B.; Yu, R.; Blakesley, R.; Gallagher, N.; Saglio, G.; Kantarjian, H.
2014Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinibHughes, T.; Lipton, J.; Spector, N.; Cervantes, F.; Pasquini, R.; Clementino, N.; Dorlhiac Llacer, P.; Schwarer, A.; Mahon, F.; Rea, D.; Branford, S.; Purkayastha, D.; Collins, L.; Szczudlo, T.; Leber, B.
2017Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemiaSopper, S.; Mustjoki, S.; White, D.; Hughes, T.; Valent, P.; Burchert, A.; Gjertsen, B.; Gastl, G.; Baldauf, M.; Trajanoski, Z.; Giles, F.; Hochhaus, A.; Ernst, T.; Schenk, T.; Janssen, J.; Ossenkoppele, G.; Porkka, K.; Wolf, D.
2013Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phaseHochhaus, A.; Saglio, G.; Larson, R.; Kim, D.; Etienne, G.; Rosti, G.; De Souza, C.; Kurokawa, M.; Kalaycio, M.; Hoenekopp, A.; Fan, X.; Shou, Y.; Kantarjian, H.; Hughes, T.
2011Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cellsTang, M.; Gonen, M.; Quintas-Cardama, A.; Cortes, J.; Kantarjian, H.; Field, C.; Hughes, T.; Branford, S.; Michor, F.